Latest Lynx1 Capital Management LP Stock Portfolio
$277Million– No. of Holdings #17
Lynx1 Capital Management LP Performance:
2024 Q2: -9.18%YTD: 31.43%2023: 69.59%
Performance for 2024 Q2 is -9.18%, and YTD is 31.43%, and 2023 is 69.59%.
About Lynx1 Capital Management LP and 13F Hedge Fund Stock Holdings
Lynx1 Capital Management LP is a hedge fund based in SAN JUAN, PR. On 03-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $136.4 Millions. In it's latest 13F Holdings report, Lynx1 Capital Management LP reported an equity portfolio of $277.2 Millions as of 30 Jun, 2024.
The top stock holdings of Lynx1 Capital Management LP are IBIO. The fund has invested 0.6% of it's portfolio in IBIO INC and NA% of portfolio in NA.
The fund showed a lot of confidence in some stocks as they added substantially to IBIO INC (IBIO).
The top stock holdings of Lynx1 Capital Management LP are IBIO. The fund has invested 0.6% of it's portfolio in IBIO INC and NA% of portfolio in NA.
The fund showed a lot of confidence in some stocks as they added substantially to IBIO INC (IBIO).
Lynx1 Capital Management LP Equity Portfolio Value
Last Reported on: 14 Aug, 2024
Lynx1 Capital Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Lynx1 Capital Management LP made a return of -9.18% in the last quarter. In trailing 12 months, it's portfolio return was 95.21%.
New Buys
| Ticker | $ Bought |
|---|---|
| cullinan therapeutics inc | 6,580,510 |
| allogene therapeutics inc | 5,191,930 |
| longboard pharmaceuticals in | 4,522,580 |
| pieris pharmaceuticals inc | 426,756 |
| kiniksa pharmaceuticals intl | 177,365 |
| korro bio inc | 128,706 |
| vyne therapeutics inc | 31,902 |
New stocks bought by Lynx1 Capital Management LP
Additions
| Ticker | % Inc. |
|---|---|
| c4 therapeutics inc | 89.3 |
| stoke therapeutics inc | 40.26 |
| ibio inc | 40.13 |
| gh research plc | 19.82 |
| passage bio inc | 4.37 |
Additions to existing portfolio by Lynx1 Capital Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| cabaletta bio inc | -76.37 |
| bionomics limited | -26.37 |
| merus n v | -20.03 |
Lynx1 Capital Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| alpine immune sciences inc | -89,316,200 |
| nektar therapeutics | -1,932,710 |
| kinnate biopharma inc | -5,269,740 |
| autolus therapeutics plc | -8,869,220 |
| silence therapeutics plc | -11,375,500 |
| pieris pharmaceuticals inc | -1,608,340 |
Lynx1 Capital Management LP got rid off the above stocks
Sector Distribution
Lynx1 Capital Management LP has about 83% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 83 |
| Others | 17 |
Market Cap. Distribution
Lynx1 Capital Management LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 55 |
| MID-CAP | 25.8 |
| UNALLOCATED | 17 |
| MICRO-CAP | 1.4 |
Stocks belong to which Index?
About 32.5% of the stocks held by Lynx1 Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 67.5 |
| RUSSELL 2000 | 32.5 |
Lynx1 Capital Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Lynx1 Capital Management LP
Lynx1 Capital Management LP has 17 stocks in it's portfolio. About 98.9% of the portfolio is in top 10 stocks. CCCC proved to be the most loss making stock for the portfolio. MRUS was the most profitable stock for Lynx1 Capital Management LP last quarter.
Last Reported on: 14 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ALLO | allogene therapeutics inc | 1.87 | 2,228,300 | 5,191,930 | new | |||
| ALPN | alpine immune sciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AUTL | autolus therapeutics plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CABA | cabaletta bio inc | 1.33 | 492,103 | 3,680,930 | reduced | -76.37 | ||
| CCCC | c4 therapeutics inc | 11.47 | 6,880,530 | 31,788,000 | added | 89.3 | ||
| CGEM | cullinan therapeutics inc | 2.37 | 377,323 | 6,580,510 | new | |||
| CNTA | centessa pharmaceuticals plc | 0.06 | 17,400 | 157,122 | unchanged | 0.00 | ||
| IBIO | ibio inc | 0.64 | 840,763 | 1,774,010 | added | 40.13 | ||
| LBPH | longboard pharmaceuticals in | 1.63 | 167,317 | 4,522,580 | new | |||
| MRUS | merus n v | 25.76 | 1,206,710 | 71,400,900 | reduced | -20.03 | ||
| NKTR | nektar therapeutics | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| PASG | passage bio inc | 1.45 | 5,057,630 | 4,016,770 | added | 4.37 | ||
| PIRS | pieris pharmaceuticals inc | 0.15 | 43,499 | 426,756 | new | |||
| PIRS | pieris pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| STOK | stoke therapeutics inc | 25.27 | 5,185,190 | 70,051,900 | added | 40.26 | ||
| TCRX | tscan therapeutics inc | 11.03 | 5,224,600 | 30,563,900 | unchanged | 0.00 | ||
| VYNE | vyne therapeutics inc | 0.01 | 16,194 | 31,902 | new | |||
| gh research plc | 16.68 | 3,966,730 | 46,252,000 | added | 19.82 | |||
| bionomics limited | 0.17 | 599,673 | 459,949 | reduced | -26.37 | |||
| kiniksa pharmaceuticals intl | 0.06 | 9,500 | 177,365 | new | ||||